HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
1 . A conjugate comprising an active agent coupled, via a linker, to at least one HSP90 targeting moiety, wherein the active agent comprises a radioactive agent or a chelating agent for a radioactive agent.
2 . The conjugate of claim 1 , wherein the radioactive agent comprises a radioisotope.
3 . The conjugate of claim 2 , wherein the radioisotope is I-124, I-131, In-111, Re-186, Re-188, Y-90, Bi-212, At-211, Sr-89, Ho-166, Sm-153, Cu-60, Lu-177, Ac-225, Bi-213, Th-227, Pb-212, Ra-223, P-32, Sc-47, Br-76, Br-77, Rh-105, Pd-103, Ag-111, Tc-99m, Co-57, Ga-66, Ga-67, Ga-68, Kr-81m, Rb-82, Sr-92, Tl-201, Y-86, Zr-89, C-11, N-13, O-15, F-18, Y-86, Bi-212, At-211, Zr-89, Sr-89, Ho-166, Sm-153, Cu-67, Cu-64, Pb-203, Bi-213, Th-227, Pb-212, Ra-223, P-32, Sc-47, Br-77, Rh-105, Pd-103, Ag-111, Pr-142, Pm-149, Gd-159, Ir-194 and Pt-199.
4 . The conjugate of claim 1 , wherein the active agent comprises a chelating agent that binds to a radioisotope.
5 . The conjugate of claim 4 , wherein the chelating agent is a polyaminocarboxylate agent.
6 . The conjugate of claim 5 , wherein the chelating agent is ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), 1,4,7,10-tetra-azacylcododecane-N,N′,N″,N′″-tetraacetic acid (DOTA), DOTAGA, or derivatives thereof.
7 . The conjugate of claim 4 , wherein the chelating agent is a macrocyclic agent.
8 . The conjugate of claim 7 , wherein the chelating agent is 1,4,7-Triazacyclononane-N,N′,N″-triacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (TETA), 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N″,N′″,N″″-pentaacetic acid (PEPA), 1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N″,N′″,N″″,N′″″-hexaacetic acid (HEHA), or derivatives thereof.
9 . The conjugate of claim 1 , wherein the conjugate comprises two HSP90 targeting moieties.
10 . The conjugate of claim 1 , wherein the HSP90 targeting moiety is an HSP90 inhibitor.
11 . The conjugate of claim 10 , wherein the HSP90 inhibitor is a small molecule.
12 . The conjugate of claim 11 , wherein the HSP90 inhibitor is selected from the group consisting of Ganetespib, Luminespib (AUY-922, NVP-AUY922), Debio-0932, MPC-3100, or Onalespib (AT-13387), SNX-2112, 17-amino-geldanamycin hydroquinone, PU-H71, AT13387, and derivatives/analogs thereof.
13 . The conjugate of claim 10 , wherein the HSP90 targeting moiety is ganetespib or a derivative thereof.
14 . The conjugate of claim 13 , wherein the HSP90 targeting moiety is selected from the group consisting of TM1, TM2, TM3, TM4, TM5, or TM8.
15 . The conjugate of claim 10 , wherein the HSP90 targeting moiety is Onalespib or a derivative thereof.
16 . The conjugate of claim 15 , wherein the HSP90 targeting moiety is selected from the group consisting of TM6 and TM7.
17 . The conjugate of claim 1 , wherein the linker comprises an ester group, a disulfide group, an amide group, an acylhydrazone group, an ether group, a carbamate group, a carbonate group, or a urea group.
18 . The conjugate of claim 1 , wherein the linker is a cleavable linker.
19 . The conjugate of claim 1 , wherein the conjugate has a molecular weight of less than about 50,000 Da, less than about 40,000 Da, less than about 30,000 Da, less than about 20,000 Da, less than about 15,000 Da, less than about 10,000 Da, less than about 8,000 Da, less than about 5,000 Da, less than about 3,000 Da, less than 2000 Da, less than 1500 Da, less than 1000 Da, or less than 500 Da.
20 . The conjugate of claim 1 , wherein the conjugate comprises at least one ganetespib or its derivative as the HSP90 targeting moiety and a lutetium atom.
21 . The conjugate of claim 1 , wherein the conjugate is selected from the group consisting of Conjugate 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 or a pharmaceutically acceptable salt thereof.
22 . The conjugate of claim 1 , wherein the conjugate is a radioactive analog of a conjugate selected from the group consisting of Conjugate 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 or a pharmaceutically acceptable salt thereof.
23 . The conjugate of claim 22 , wherein the conjugate is a Lu177 ( 177 Lu) analog of a conjugate selected from the group consisting of Conjugate 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 or a pharmaceutically acceptable salt thereof.
24 . The conjugate of claim 1 , wherein the conjugate comprises a reacting group that binds to a serum protein.
25 . The conjugate of claim 24 , wherein the serum protein is albumin.
26 . The conjugate of claim 24 , wherein the conjugate is Conjugate 10 or its radioactive analogs, or a pharmaceutically acceptable salt thereof.
27 . The conjugate of claim 26 , wherein the conjugate is a Lu177 ( 177 Lu) analog of Conjugate 10.
28 . A pharmaceutical composition comprising the conjugate of claim 1 and at least one pharmaceutically acceptable excipient.
29 . A method of reducing cell proliferation comprising administering a therapeutically effective amount of at least one conjugate of claim 1 to the cell.
30 . The method of claim 29 , wherein the cell is a cancer cell.
31 . The method of claim 30 , wherein the cancer cell is a small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.
32 . A method of treating cancer, comprising administering the pharmaceutical composition of claim 28 .
33 . The method of claim 32 , wherein the cancer is small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.